Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Smallcap stocks in favour today
Wed, 2 Jan 01:30 pm

The Indian markets continued to trade well above the dotted line during the post noon trading session. Barring stocks from the FMCG space, buying activity is being witnessed across the board with those from the capital goods, consumer durables and oil and gas spaces being the top performers.

The Sensex today is trading higher by about 155 points (up 0.8%), while NSE- Nifty is trading higher by about 50 points (up 0.8%). Stocks from the midcap and small spaces are trading firm with the BSE Mid Cap and the BSE Small Cap indices up by 0.7% and 1% respectively. The rupee is trading at 54.34 to the US dollar.

Stocks of pharmaceutical companies are trading firm led by Aurobindo Pharma, Cipla and Dr. Reddy's. The stock of Glenmark Pharma is trading firm after reports of the company clearing the approval of the US Food and Drug Administration for Salix Pharmaceuticals' drug to treat diarrhea in HIV/AIDS patients. The drug can be used as part of the antiretroviral therapy, which is a combination of medicines used to treat HIV infection. Glenmark will be supplying the active pharmaceutical ingredients (APIs) for the drug to Salix in for global markets (ex-China). In another development, the company has also received approval from USFDA for Rizatriptan Benzonate Tablets, which are the generic versions of Merck's Maxalt Tablets. These medicines are used to treat migraine. As per the company, Rizatriptan Benzonate tablets had US sales of US$ 333 m in a year (ended September 2012).

Stocks of auto companies are trading firm led by Bajaj Auto, Maruti Suzuki and Ashok Leyland. The stock of two wheeler major Bajaj auto hit its 52-week high levels today on the back of the company reporting good sales volumes for the month of December 2012. The company's two wheeler sales volumes were up by 13% YoY as compared to the same month last year, while its commercial vehicles sales volumes were up by 9% YoY. As per the company, the consolidated sales figure and export figures are up by 13% and 5% respectively. Bajaj Auto's sales volumes growth figures are better than those of its counterpart Hero Honda, which reported flattish volume growth for the same month.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Smallcap stocks in favour today". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.